A substantial need persists for pharmacologic therapies that offer effective symptom control with improved pharmacokinetic properties, fewer adverse reactions, and improved tolerance. Chronic disorders such as hyperkinetic movement disorders, Alzheimer’s agitation, diabetic nephropathy, schizophrenia, and major depressive disorder can be severely debilitating. Without known cures, treatment of these disorders relies heavily on symptomatic control – a challenge with currently available therapies. Deuteration can improve the pharmacokinetic and toxicological properties of many common and available agents, thereby addressing the many limitations of current therapies and substantial unmet needs that persist within medical treatment. This activity will discuss its process, utility within drug development (i.e. prolonged plasma half-life, reduced metabolic variability, fewer lower total daily doses, improved tolerance, etc.), and clinical trials investigating the efficacy of deuterium-containing agents within specific therapeutic areas.